INFORMATION DISCLOSURES
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of

Sheet

| | Complete if Known | 至 | |
|------------------------|--------------------|-----|----------|
| Application Number | 09/142,557 | 8 | ſΑ |
| Filing Date | September 11, 1998 | 4 | |
| First Named Inventor | Linda M. PILARSKI | ES. | <u> </u> |
| Group Art Unit | 1623 | 16 | 2(|
| Examiner Name | K. Fonda | 00/ | 1012 |
| Attorney Docket Number | 205220 | 290 | |
| | | | |

| | U.S. PATENT DOCUMENTS | | | | | | | |
|----------------------|-----------------------|---------------------------------|-----------|-------------------------------|------------------------|-------------------------------|--|--|
| | | U.S. Patent Document | | | | | | |
| Examiner Initials | Doc. No. | Application or Patent Number | Kind Code | Name of Patentee or Applicant | Date of Publication | Filing Date If Appropriate | | |
| KKF | AV | 5,079,236 | Α | Drizen et al. | 01/07/92 | | | |
| YXF | AW | 5,646,129 , | Α | Callegaro et al. | 07/08/97 | | | |
| KKF | AX | 5,817,644 | Α | Gustafson | 10/06/98 | | | |
| KKF | AY | 6,013,641 | Α | Lussow et al. | 01/11/00 | | | |
| KKF | AZ | 6,069,135 | Α | Falk et al. | 05/30/00 | | | |

| | | | | FC | PREIGN PATENT DOCUMENTS | | | |
|-------------------------|-------------|--------|---------------------------------|--------------|---|---------------------|-----|------|
| Foreign Patent Document | | ent | | | Translation | | | |
| Examiner Initials | Doc. No. | Office | Application or Patent Number | Kind Code | Name of Patentee or Applicant | Date of Publication | Yes | No*+ |
| KKF | ВА | WO | 91/04058 | A2 | Norpharmco Inc. et al. | 04/04/91 | | |
| KA- | BB | wo | 93/16732 | A1 | Norpharmco Inc. et al. | 09/02/93 | | |
| YVF. | ВС | WO | 93/16733 | A1 | Norpharmco inc. et al. | 09/02/93 | | |
| KKI | BD | WO | 94/23725 | A1 | Norpharmco Inc. et al. | 10/27/94 | | |
| KKF | BE | wo | 95/30423 | A2 | Norpharmco Inc. et al. | 11/16/95 | | |
| CKF | BF | wo | 96/06622 | A1 | Hyal Pharmaceutical Corporation et al. 03/07/96 | | | |
| KKF | BG | WO | 97/03699 | A1 | Hyal Pharmaceutical Corporation et al. 02/06/97 | | | |
| KKF | ВН | wo | 97/15330 | A1 | Hyal Pharmaceutical Australia Limited 05/01/97 et al. | | | |
| KE | ВІ | wo | 97/25051 | A1 | Hyal Pharmaceutical Corporation et al. 07/17/97 | | | |
| KKE | ВJ | WO | 98/13024 | A2 | Hyal Pharmaceutical Corporation et al. | 04/02/98 | | |
| KKF | вк | wo | 98/17320 | A1 | Hyal Pharmaceutical Corporation et al. | 04/30/98 | | |
| KKF | ВL | wo | 98/52590 | A2 | Hyal Pharmaceutical Corporation et al. 11/26/98 | | | |
| KKS | ВМ | wo | 99/55230 | A1 | Hyal Pharmaceutical Corporation et al. | 11/04/99 | | |
| | | | | | | | | |

| OTHER - NON PATENT LITERATURE DOCUMENTS | | | | | |
|---|----|--|--|-------------|--|
| Examiner Doc. Initials No. | | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item | | Translation | |
| | | (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | | | |
| KRE | BN | ALHO et al., <i>J. Cell. Biol.</i> , 108, 1557-1565 (1989) | | | |
| KKE | во | KELLEY et al., J. Dermatol. Surg. Oncol., 16 (11), 1039-1042 (1990) | | | |
| | BP | Martindale The ExtraPharmacopoeia, Reynolds et al. Editors, The Pharmaceutical | | Ì | |
| KKR | | Press, London, pp. 234-235 (1982) | | _ | |
| KKF | BQ | The Merch Index, Ninth Edition, Merch & Co., Inc., Rahway, New Jersey, p. 407, no. 3058 (1976) | | | |
| KKE | BR | TRABUCCHI et al., Int. J. Tiss. Reac., VIII (6), 533-544 (1986) | | | |
| RS | BS | Webster's Ninth New College Dictionary, Merriam-Webster Inc., Springfiled, | | | |
| KKF 3 | | Massachusetts, p. 1256 (1990) | | <u> </u> | |
| KKF | ВТ | WEST et al., Experimental Cell Research, 183, 179-196 (1989) | | | |

| Examiner Signature | , | KK anda | Date Considered | 11-18-02 |
|--------------------|---|---------|-----------------|----------|
| | _ | , | | |

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).